Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | CDC25B | P30305 | 2/20 | 0.32 |
| ▸ | GJB2 | P29033 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23960007 | 0.91 | PDE2A (0.34) | PDE2AHSPA5EGLN2TNK2HTR1A | |
| SCHEMBL23960011 | 0.91 | PIK3CD (0.36) | PDE2AHSPA5EGLN2HTR1A | |
| SCHEMBL23960050 | 0.90 | PDE2A (0.34) | PDE2AHSPA5EGLN2TNK2HTR1A | |
| SCHEMBL23960051 | 0.90 | PDE2A (0.36) | PDE2AHSPA5EGLN2TNK2HTR1A | |
| SCHEMBL29727834 | 0.86 | PDE2A (0.35) | PDE2AHSPA5HTR1APTPN1CDC25B | |
| SCHEMBL20553048 | 0.86 | PDE2A (0.35) | PDE2AHSPA5HTR1APTPN1CDC25B | |
| SCHEMBL20477154 | 0.86 | PDE2A (0.35) | PDE2AHSPA5HTR1APTPN1CDC25B | |
| SCHEMBL17712276 | 0.86 | PDE2A (0.35) | PDE2AHSPA5HTR1APTPN1CDC25B | |
| SCHEMBL12243178 | 0.86 | PDE2A (0.35) | PDE2AHSPA5HTR1APTPN1CDC25B | |
| SCHEMBL27086511 | 0.86 | PDE2A (0.35) | PDE2AHSPA5HTR1APTPN1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | PNP, TYMP, PIGS | PDE2A 536/4885HSPA5 4179/4885EGLN2 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.